Back to Search
Start Over
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
- Source :
-
International journal of molecular sciences [Int J Mol Sci] 2020 Dec 15; Vol. 21 (24). Date of Electronic Publication: 2020 Dec 15. - Publication Year :
- 2020
-
Abstract
- CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives.
- Subjects :
- B-Lymphocytes immunology
B-Lymphocytes pathology
Humans
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell metabolism
Lymphoma, B-Cell drug therapy
Lymphoma, B-Cell metabolism
Receptors, Chimeric Antigen immunology
Receptors, Chimeric Antigen metabolism
Antibodies, Monoclonal therapeutic use
Antigens, Neoplasm immunology
Antigens, Neoplasm metabolism
Antineoplastic Agents, Immunological therapeutic use
B-Lymphocytes metabolism
Immunotherapy methods
Leukemia, Lymphocytic, Chronic, B-Cell immunology
Lymphoma, B-Cell immunology
Tetraspanins immunology
Tetraspanins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1422-0067
- Volume :
- 21
- Issue :
- 24
- Database :
- MEDLINE
- Journal :
- International journal of molecular sciences
- Publication Type :
- Academic Journal
- Accession number :
- 33333768
- Full Text :
- https://doi.org/10.3390/ijms21249531